Clinical Trials on Metastatic Sporadic Medullary Thyroid Cancer in Spain

Total 550 results

Genmab
Merck Sharp & Dohme LLC; BioNTech SE

Recruiting

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Non Small Cell Lung Cancer Metastatic

United States, Spain, Netherlands, Italy, France, United Kingdom, Poland, Germany, Portugal
Janssen-Cilag Ltd.

Recruiting

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide (ArtemisPRO)

Metastatic Hormone-sensitive Prostate Cancer

France, Germany, Spain, Greece, United Kingdom, Austria
Amgen

Completed

Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

Locally Recurrent and Metastatic Breast Cancer

United States, United Kingdom, Denmark, Poland, Belgium, Hungary, Spain, Austria, France, Australia, Netherlands, Finland, India
Bayer
Amgen

Completed

Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects

Metastatic Colorectal Cancer

Belgium, Italy, Poland, Spain, Russian Federation, United States, Hungary, Romania, United Kingdom, Ukraine
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

Metastatic Colorectal Cancer

Canada, Hungary, United States, Australia, Belgium, Chile, Colombia, France, Germany, Japan, Korea, Republic of, Latvia, Lithuania, Russian Federation, South Africa, Spain, Turkey, Ukraine
Bayer

Completed

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Metastatic Colorectal Cancer

Belgium, Italy, Spain, Canada, Japan, Czech Republic, United States, Australia, France, Hungary, China, Germany, Israel, Netherlands, Turkey, Portugal, Brazil, Switzerland, Argentina
Merus N.V.
Chiltern International Inc.; Q2 Solutions; Oncology Therapeutic Development (OTD) and other collaborators

Recruiting

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Gastric Cancer | Colorectal Cancer | NSCLC | Head and Neck Squamous Cell Carcinoma | HNSCC | Advanced/Metastatic Solid Tumors | Gastroesophageal-junction Cancer

United States, Spain, Belgium, France, Netherlands, United Kingdom
Byondis B.V.

Completed

Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985

Metastatic Breast Cancer

France, Belgium, Spain
Genentech, Inc.

Recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Korea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
Sirtex Medical

Completed

FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer (FOXFIREGlobal)

Colorectal Cancer Metastatic

United States, France, Korea, Republic of, Australia, Israel, Singapore, Belgium, Taiwan, Spain, New Zealand, Portugal, Germany, Italy
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

United States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
Hoffmann-La Roche

Completed

Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma

Metastatic Cancers

Spain
Galician Research Group on Digestive Tumors
LEO Pharma

Recruiting

TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer (PROTINCOL)

Thromboembolism | Colorectal Cancer Metastatic

Spain
Synta Pharmaceuticals Corp.

Terminated

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer (GALAXY)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV

United States, Belgium, Bosnia and Herzegovina, Canada, Croatia, Czech Republic, Germany, Poland, Romania, Russian Federation, Serbia, Spain, United Kingdom
Hoffmann-La Roche

Completed

A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Carcinoma, Hepatocellular | Liver Metastases | Biliary Tract Cancer | Secondary Liver Cancer

Korea, Republic of, Denmark, Spain, Taiwan, United States, Hong Kong
Mirati Therapeutics Inc.

Active, not recruiting

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Metastatic Colorectal Cancer | Advanced Colorectal Cancer

United States, Denmark, Finland, Italy, Spain, Belgium, Romania, Taiwan, Thailand, France, Germany, Korea, Republic of, China, Malaysia, Hong Kong, Australia, Austria, Puerto Rico, Singapore, Canada, Portugal, Poland, Greece, United Kingdom and more
Bayer
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)

Prostate Cancer Non-Metastatic | Castration-Resistant

Belgium, France, Poland, Spain, Canada, United States, Estonia, Portugal, Taiwan, Japan, Russian Federation, Finland, Germany, Austria, Czechia, Hungary, Australia, Brazil, South Africa, Latvia, Italy, United Kingdom, Turkey, Serbia, Ro... and more
Achieve Life Sciences
PRA Health Sciences

Completed

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Urologic Neoplasms | Metastatic Bladder Cancer | Urinary Tract Neoplasms

Spain, United States, Canada, Italy, Poland, Germany, France
Sirtex Medical

Recruiting

Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry) (SIRtain)

Unresectable Hepatocellular Carcinoma (HCC) | Liver Metastases From Colorectal Cancer (mCRC)

Spain, United Kingdom, France
Pfizer

Completed

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

Carcinoma, Pancreatic Ductal

United States, Netherlands, Canada, Hungary, Spain, United Kingdom, France, Austria, Belgium, Germany, Ireland, Korea, Republic of, Russian Federation, Sweden, South Africa, Italy, Singapore, Taiwan, Australia, India, Argentina, J... and more
Enliven Therapeutics

Recruiting

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2)

HER2-positive Metastatic Breast Cancer | HER2 Gene Mutation | HER2 Mutant Non-small Cell Lung Cancer | HER2 Amplification

Spain, United States, Korea, Republic of, Taiwan, Italy, Australia, France
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Active, not recruiting

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. (SOLSTICE)

Metastatic Colorectal Cancer

United Kingdom, Lithuania, France, Sweden, Australia, Latvia, Spain, Poland, Argentina, Austria, Brazil, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, Ireland, Italy, Netherlands, Portugal, Romania, Russian Federation, Slovakia, Ukrai...
BeiGene

Active, not recruiting

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer, Stage IV | Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)

United States, China, Korea, Republic of, France, Spain, Australia, Austria
Novartis

Completed

Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Subfoveal Choroidal Neovascularization (CNV) | Secondary to Age-related Macular Degeneration (AMD)

Germany, Belgium, Spain, Netherlands, United Kingdom, Hungary, Turkey, Israel, Portugal, Australia
Bayer

Active, not recruiting

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer (REASSURE)

Metastatic Castration-resistant Prostate Cancer

United States, Austria, Czechia, Israel, Italy, Germany, United Kingdom, France, Mexico, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Denmark, Sweden, Argentina, Portugal
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): (PRESERVE1)

Colorectal Cancer Metastatic | Chemotherapeutic Toxicity | Myelosuppression-Adult

China, Spain, United States, Hungary, United Kingdom, Poland, Ukraine, Italy
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Active, not recruiting

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Advanced or Metastatic NSCLC

United States, Spain, Taiwan, Japan, Italy
BeiGene

Recruiting

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Spain, France, Malaysia, Italy, Canada, Thailand, Georgia, Brazil, Korea, Republic of, Singapore, Moldova, Republic of, Romania
Astellas Pharma Europe Ltd.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone (PRESIDE)

Metastatic Castration Resistant Prostate Cancer

Belgium, France, Spain, Austria, Czechia, Germany, Greece, Italy, Netherlands, Norway, Poland, Russian Federation, Sweden, Switzerland, Turkey, United Kingdom
Taiho Oncology, Inc.

Recruiting

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Pancreatic Cancer | Esophageal Adenocarcinoma | Esophageal Squamous Cell Cancer | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer | Siewert Type 1 GEJ Cancer

United States, Spain, Germany, France
Seagen Inc.
National Cancer Institute (NCI); Academic and Community Cancer Research United

Completed

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

Metastatic Colorectal Adenocarcinoma

United States, Spain, Belgium, France, Italy
AstraZeneca
Daiichi Sankyo

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (DL03)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Korea, Republic of, Italy, Poland, Malaysia, Taiwan, Thailand, United States, France, Netherlands, Philippines, Canada, Singapore, Spain, Turkey, Australia, Belgium, Israel
MacroGenics

Completed

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Cervical Cancer | Hematologic Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Small-cell Lung Cancer | TNBC - Triple-Negative Breast Cancer | HER2-positive Advanced Solid Tumors

Hong Kong, United States, Thailand, Australia, Spain, Bulgaria, Poland, Ukraine
AbbVie

Active, not recruiting

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Cancer | Advanced Solid Tumors | Metastatic Solid Tumors | Triple-Negative Breast Cancer (TNBC) | Non-small-cell-lung-cancer (NSCLC)

United States, Australia, France, Israel, Spain, Taiwan
Novartis Pharmaceuticals

Terminated

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Ovarian Cancer | Non-small Cell Lung Cancer (NSCLC) | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Metastatic Castration Resistant Prostate Cancer (mCRPC) | Colorectal Cancer Microsatellite Stable (MSS)

Canada, Australia, Singapore, United States, Japan, Spain, United Kingdom
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) (CRYSTAL)

Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer

Sweden, Australia, Brazil, Bulgaria, France, Italy, Korea, Republic of, Russian Federation, South Africa, Spain, Turkey, United Kingdom, Germany, Hungary, Poland, Romania, Austria, Belgium, Finland, Netherlands, Slovakia, Greece, Ta... and more
Pfizer
Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. Ltd; Pierre Fabre Medicament

Completed

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC)

BRAF V600E-mutant Metastatic Colorectal Cancer

United States, Spain, Korea, Republic of, United Kingdom, Australia, Czechia, Taiwan, Belgium, France, Hungary, Canada, Japan, Russian Federation, Netherlands, Israel, Germany, Turkey, Austria, Brazil, Poland, Italy, Argentina, Chile, Denmar... and more
Mologen AG

Unknown

Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment (IMPALA)

Metastatic Colorectal Cancer

France, Spain, Germany, United Kingdom, Italy, Belgium, Austria, Estonia
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Prostate Cancer Metastatic

Canada, Germany, United States, Israel, Puerto Rico, Taiwan, Korea, Republic of, Australia, Chile, China, France, Norway, Czechia, Finland, Hong Kong, Netherlands, Poland, Spain, Sweden, Turkey, Denmark, Hungary, Italy, United Kingdom, ... and more
GlaxoSmithKline

Completed

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

Metastatic Cervical Cancer | Neoplasms, Uterine Cervix

United States, Germany, Spain, Thailand, Belgium, Italy, Argentina, Canada, Ireland, India, France, Estonia, Mexico
Eli Lilly and Company

Active, not recruiting

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY)

Metastatic Non-Small Cell Lung Cancer

France, Spain, United States, Italy, Canada, Taiwan, Hong Kong, Japan, Turkey, Korea, Republic of, United Kingdom, Germany, Romania, Greece
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States, Italy, Spain, Belgium, Canada, France, Korea, Republic of, United Kingdom, Brazil, Czechia, Turkey, Australia, Chile, Germany, Japan, Netherlands, Slovakia
Sanofi
Regeneron Pharmaceuticals

Completed

Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Colorectal Cancer Metastatic

Italy, Spain, United Kingdom, Czechia, Russian Federation, Norway, Thailand, Chile, Israel, Brazil, United States, Belgium, Canada, Denmark, Finland, Germany, Ireland, Lebanon, Mexico, Netherlands, Puerto Rico, Sweden, Turkey
Vaxon Biotech

Completed

Efficacy Study of Vx001 Vaccine in NSCLC Patients

Non-small Cell Lung Cancer Metastatic

Germany, Greece, Spain, Romania, France, Italy, Czechia, Poland
Janssen Research & Development, LLC

Completed

A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

Metastatic Prostate Cancer

United States, Korea, Republic of, Australia, Poland, Taiwan, France, Thailand, Malaysia, Russian Federation, Canada, Bulgaria, Italy, Spain, Turkey, Sweden, Israel, Belarus, Ukraine, Brazil, Argentina, Belgium, Denmark, United Kingdom and more
Hoffmann-La Roche

Completed

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)

Metastatic Prostate Cancer

United States, Belgium, France, United Kingdom, Canada, Korea, Republic of, China, Denmark, Greece, Ireland, Portugal, Spain, Italy, Brazil, Mexico, Australia, Thailand, Japan, Costa Rica, Israel, Russian Federation, Austria, Hungary, Norwa... and more
Bayer

Active, not recruiting

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Spain, Korea, Republic of, United Kingdom, Australia, Hong Kong, Singapore, Taiwan, Lithuania, Russian Federation, Turkey, France, Israel, Czechia, Italy, Germany, Finland, Austria, Poland, Hungary
Hoffmann-La Roche

Active, not recruiting

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

Metastatic Melanoma | Non-small Cell Lung Cancer (NSCLC) | Solid Tumors | Esophageal Squamous Cell Carcinoma (ESCC) | Small Cell Lung Cancer (SCLC)

United States, Korea, Republic of, Denmark, France, Spain, New Zealand
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Metastatic Non-Small Cell Lung Cancer

Poland, United States, Argentina, Austria, Brazil, Chile, China, Colombia, France, Germany, Israel, Japan, Korea, Republic of, Mexico, Spain, Taiwan, Thailand, Turkey, United Kingdom
MacroGenics

Active, not recruiting

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Colorectal Cancer | Advanced Cancer | Prostate Cancer Metastatic | Cutaneous Melanoma | Solid Tumor, Adult | Squamous Cell Non Small Cell Lung Cancer

United States, Spain, Bulgaria, Poland, Ukraine

Clinical Trials on Metastatic Sporadic Medullary Thyroid Cancer in Spain

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations